Company Profile
Cocrystal Pharma Stock Price, News & Catalysts
- Ticker:
- COCP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.09 USD (-2.68%)
Close
Last updated: August 17, 2026
14.5M USD
Market cap
Why the stock is moving
Following the latest company update, “Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors”, COCP closed down 2.68% at $1.09 on Aug 17, 2026. The move occurred in the trading session associated with this company update.
Company overview
Broad-Spectrum Antiviral Developer
Cocrystal Pharma uses a structure-based drug discovery platform to develop broad-spectrum antiviral medicines targeting conserved regions of viral proteases and polymerases. The strategy is intended to maintain activity across viral variants while minimizing off-target effects.
CDI-988 Norovirus Program
CDI-988 is an oral antiviral candidate for norovirus being evaluated in a Phase 1b human challenge study conducted with Emory University and the University of North Carolina. The trial includes both prevention and treatment cohorts.
Human Challenge Development Model
The controlled human infection study is designed to measure symptom incidence, viral shedding, safety, and pharmacokinetics in a defined setting. This approach can generate early proof-of-concept evidence for both prophylactic and therapeutic use.
Influenza and Coronavirus Pipeline
CC-42344 is a PB2 inhibitor for pandemic and seasonal influenza A. Cocrystal is also developing an inhaled formulation and generating leads for influenza A and B, while CDI-988 may have applications in coronavirus infections.
Future catalysts
- The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
- An additional Phase 2a study of oral CC-42344 in influenza A is planned.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cocrystal Pharma (COCP)?
Cocrystal Pharma (COCP) most recently closed at 1.09 USD, a -2.68% move versus the previous session.
What is the market cap of Cocrystal Pharma (COCP)?
Cocrystal Pharma currently has a market capitalization of 14.5M USD on BioPharmSignal.
What does Cocrystal Pharma do?
Broad-Spectrum Antiviral Developer Cocrystal Pharma uses a structure-based drug discovery platform to develop broad-spectrum antiviral medicines targeting conserved regions of viral proteases and polymerases. The strategy is intended to maintain activity across viral variants while minimizing off-target effects. CDI-988 Norovirus Program CDI-988 is an oral...
On which exchange is COCP stock listed?
Cocrystal Pharma (COCP) is associated with NASDAQ, United States, Biopharma.
What is CDI-988?
The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
Which conditions is Cocrystal Pharma targeting with CDI-988?
The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
How does Cocrystal Pharma describe recent progress with CDI-988?
The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
What is CC-42344?
Influenza and Coronavirus Pipeline CC-42344 is a PB2 inhibitor for pandemic and seasonal influenza A.